MedTrace Logo

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

NCT04566003 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-07-12

No results posted yet for this study

Summary

The study aims to compare tau targeted radiotracers \[18F\]GTP1 and \[18F\]PI-2620 or \[18F\]MK-6240 in subjects with normal cognition or prodromal to moderate Alzheimer's disease (AD).

Conditions

  • Alzheimer Disease (AD)

Interventions

DRUG

[18F]GTP1

Participants will receive a bolus IV of approximately 7mCi of \[18F\]GTP1 radiotracer.

DRUG

[18F]PI-2620

Participants will receive a bolus IV of approximately 5mCi of \[18F\]PI-2620 radiotracer.

DRUG

[18F]MK-6240

Participants will receive a bolus IV of approximately 5mCi of \[18F\]MK-6240 radiotracer.

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Genentech, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-26
Primary Completion
2023-06-27
Completion
2023-06-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04566003 on ClinicalTrials.gov